Biomarkers, Pharmacological; Carbon Radioisotopes; Fluorine Radioisotopes; Gallium Radioisotopes; Molecular Imaging; Positron-Emission Tomography; Radiochemistry; Radionuclide Imaging; Radiopharmaceuticals
The development of molecular imaging probes for PET is gaining more and more interest since applied diagnostics and stratification of patients for pinpointed treatment are the methods of choice in a 4P medicine environment. Hence, selective and specific radioactive tracers incorporating positron emitter nuclides are needed and their development requires cooperative research between (radio)chemists, (radio)pharmacists, clinicians, physicists, nutrion scientists, system biologists, network analyticians and technologists - to name just a few!
My special focus lies on the development of novel small-molecule PET-radiotracers and their translational evaluation to bring them into (first) in-human use. Furthermore, I pay special attention to the use of the molecular in-vivo information out of PET imaging in combination to "omics"-data (e.g. NGS, metabolomics, proteomics, immunolomics). For this purpose, I also serve as the scientific coordinator of Vienna based activities for the "Center of Biomarker Research in Medicine" (CBmed GmbH), a COMET K1 research centre based in Graz.
Techniques, methods & infrastructure
Medicinal Radiochemistry at the Division of Nuclear Medicine of the Medical University of Vienna comprises of all necessary equipment and infrastructure to develop novel radiopharmaceuticals, provide full radiopharmaceutical quality control and enable pre-clinical testing as a prerequisite for translation into a clinical setting.
- Medical Cyclotron (GE PETtrace 860)
- Several Hot-Cells (=fully shielded fume hoods; partly LAF-boxes; Comecer, van Gahlen)
- A variety of fully automated synthesizers (e.g. GE FASTlab; Scintomics GRP+; Elysia-Raytest GAIA; EZAG PharmTracer; GE TRACERlab FxC Pro; Advion NanoTek)
- Specialized QC equipment (radio-TLC, radio-HPLC, GC, ...)